Every year, 5000 Norwegian men is diagnosed with prostate cancer and approximately 20% of them die. Cryoimmunotherapy is a new treatment for prostate cancer that mobilizes the patient's own immune system to attack the cancer cells.

A strong transdisciplinary team of doctors at Haukeland University Hospital has started to conduct a clinical study of the treatment. By the end of 2016 the study was halfway in phase 1, and the results so far show that the treatment causes few side effects and is well tolerated by the patients. Haukeland is the first hospital in the world to test the treatment fully, and a total of 18 patients with prostate cancer will participate in the study.

The preliminary results are promising, and the treatment has been well tolerated by the patients in the clinical study.

If the results from the clinical study proves to be successful, the treatment also can be used to cure other types of cancer.

BTO is the largest shareholder in Alden Cancer Therapy II, and we have contributed with business development, finance, legal assistance, patenting and communication.

The project has received verification funding from the FORNY2020 program at the Norwegian Research Council, as well as donations from several companies and individuals.

Other projects

Washing hands, close up
4-day treatment of OCD (Obsessive-Compulsive Disorder)

A new conceptual treatment method consisting of a intensive 4-day programme for anxiety disorders.

Read more
The Holberg EEG team
Holberg EEG

SCORE (Standardised Computer-based Organised Reporting of EEG) is the new European standard for reporting EEG. It is a software with an associated database, which is used to categorise and describe EEG examinations.

Read more
Nurse taking blood sample from the heel of an infant.
New treatment for rare disease will help children

One out of 10 000 children all over the world is born with the rare metabolic disorder phenylketonuria (PKU). Researchers from Bergen develops a treatment against the disorder, and their research are promising.

Read more